

# **GIUSEPPE CURIGLIANO**

M.D. Ph.D.

## **CURRICULUM VITAE**

Head, Division of Early Drug Development, European Institute of Oncology, Milan

Member of the Executive Board of European Society of Breast Cancer Specialists (EUSOMA)

Member of the European Society of Medical Oncology Nominating Committee

Member of the Scientific Advisory Council of the International Breast Cancer Study Group  
(IBCSG)

President of the International Cardio-Oncology Society (ICOS)

Member of the European Society of Medical Oncology Press & Media Affairs Committee:  
Spokesperson coordinator for Breast cancer

National Board for Associate Professor in Medical Oncology 06/D3, 2012

Past Member of the Scientific Advisory Council of the Breast International Group (BIG)

## PERSONAL DETAILS

---

**Email Address**            [giuseppe.curigliano@ieo.it](mailto:giuseppe.curigliano@ieo.it)

**Medical Registry No**    MI-39318

**Nationalities**            Italian, Canadian

**Marital Status**          Married

**Languages**              English, Italian, basic French

## EDUCATION

---

## Catholic University of Rome and University of Pisa

<b>Lyceum Humanities Degree</b>	Summa cum laude honours, Liceo Michele Morelli, Vibo Valentia	1986
---	--	------

### Medical degrees

MD	Summa cum laude honours: “Prognostic significance of p53 in early stage colorectal cancer” Università Cattolica del Sacro Cuore, Policlinico Gemelli, Roma	1993
----	--	------

Specialist Qualification	Summa cum laude honours in Medical Oncology “Molecular diagnosis of transitional cell carcinoma by Denaturing Gradient Gel Electrophoresis (DGGE) urinalysis” Università Cattolica del Sacro Cuore, Policlinico Gemelli, Roma	1998
-----------------------------	--	------

### Science degrees

PhD	Summa cum laude honours in Clinical Pharmacology “Pharmacogenetic determinants of response to chemotherapy in bladder and non small cell carcinoma” Università di Pisa	2006
-----	---	------

MSc	Summa cum laude honours in Health Management “Clinical Pathways and Activity Based Costing in the management of early breast cancer” Università Cattolica del Sacro Cuore, Milano	2012
-----	--	------

## JOURNAL EDITORIAL BOARD o CURRENT REVIEWER

---

### Editorial Board Member

- The Breast (Co-Editor in Chief)
- European Journal of Cancer (Associate Breast Cancer Section Editor)
- Cancer Treatment Review (Associate Breast Cancer Section Editor)
- Current Opinion in Oncology (Associate Breast Cancer Section Editor)
- Cardio-Oncology (Associate Editor)
- Journal of Clinical Oncology (Breast Cancer Editor)
- Annals of Oncology (Breast Cancer Editor)
- OncoReview (Associate Editor)

### Current reviewer

- Nature Clinical Cancer Reviews
- Journal of National Cancer Institute
- The New England Journal of Medicine
- Breast Cancer Research and Treatment
- Nature Clinical Practice Oncology
- Cancer Treatment Review
- Breast Cancer Research
- British Journal of Cancer
- European Journal of Cancer
- Breast Cancer Research
- Critical Review in Hematology-Oncology
- The Lancet Oncology

## HONOURS and PRIZES

- |   |      |
|---|------|
| Prize "Tullio Terranova" for Clinical Cancer Research | 1993 |
| Prize "Istituto Toniolo" for Clinical Cancer Research | 1995 |

Susan G. Komen for the Cure Scholar	2011
Awarded “Cavaliere” by Prime Minister Mario Monti and President Giorgio Napolitano	2012
European School Oncology Umberto Veronesi Award	2016

## POSTGRADUATE FELLOWSHIPS

---

Tullio Terranova Travelling Fellow	1993
Clinical Immunology Fellowship at South Carolina Medical School, Charleston, SC, USA	1994
Istituto Toniolo Translational Research fellowship	1995
Clinical Fellowship at Columbia University Comprehensive Cancer Center, New York, NY, USA	1995-96
Federazione Italiana Ricerca sul Cancro (FIRC) Translational Research Fellowship	1997-2000

## MEDICAL ONCOLOGY CAREER

---

### **Catholic University of Rome**

Dept of Medicine, Prof. G. Folli,  
Internal Medicine Research Fellow

September 1989 - September 1991

Giovanni XXIII Institute for Cancer Research, Prof. A. Cittadini  
Molecular Biology Training Fellowship,  
Senior Lecturer in Medical Oncology

October 1991 - December 1993

**Medical University of South Carolina,  
South Carolina Medical School,  
Charleston, SC, USA**

Dept of Clinical Immunology, prof. M. La Via  
Senior Research Fellow

December 1993 - December  
1994

**Columbia University, College of Physician  
and Surgeons, Columbia Comprehensive  
Cancer Center, New York, NY, USA**

Molecular Epidemiology Lab, prof. I.B. Weinstein,  
Senior Fellow

January 1995 - February 1996

**Italian Air Force, 53° Stormo Caccia  
Chiarini, Cameri, Novara, IT**

Lieutenant, Chief Medical Officer

March 1996 – September  
1997

**European Institute of Oncology**

Senior Clinical Assistant, Phase I and Clinical  
Pharmacology Unit, Chair dr F. de Braud

January 1999 – April 2004

Deputy Director of the Division of Medical  
Oncology, Chair prof. A. Goldhirsch

May 2005 – May 2010

Co-Chair of the Division of Medical  
Oncology, Chair prof. Aron Goldhirsch

May 2010- March 2013

Chair, Early Clinical Trial Division

April 2013

**Dana Farber Cancer Institute**

2010

Visiting scientist  
Breast Cancer Program, Chair Eric P. Winer

## **MEMBERSHIP OF SOCIETIES**

---

- Italian Oncology Association (AIOM)
- European Society of Medical Oncology (ESMO)
- American Society for Clinical Oncology (ASCO)
- American Association for Cancer Research (AACR)
- Society for Immunotherapy of Cancer (SITC)
- Italian Society of Clinical Pharmacology (SIF)
- International Cardio-Oncology Society (ICOS)
- Breast International Group (BIG)
- International Breast Cancer Study Group (IBCSG)
- European Society of Breast Cancer Specialists (EUSOMA)

## MEMBERSHIP OF EXECUTIVE COMMITTEES

---

### Local

- ❑ European Institute of Oncology
  - Committee of Heads of Clinical Divisions
  - Committee of IEO Education
  - Committee of Clinical Pharmacology Evaluation
  - Committee of Clinical Pathways and Activity Based Costing assessment

### National

- ❑ Expert Board for Drug Evaluation of Agenzia Italiana del Farmaco (AIFA), Board Member (2007-Present)
- ❑ Clinical Research Council of Associazione Italiana Oncologia Medica, Molecular and Cell Medicine Board, Committee Member (2011-Present)

### International

- ❑ Expert Board of European Medicines Agency (EMA), Assessors Committee Member (2007-2013)
- ❑ Scientific Advisory Council, International Breast Cancer Study Group, Committee Member (2009-Present)
- ❑ St Gallen Early Breast Cancer Consensus Conference, Scientific Committee Member (2009-Present)
- ❑ International Cardio-Oncology Society, Founding Member and Scientific Secretary (2009-Present)
- ❑ European School of Oncology, Faculty Member (2009-Present)
- ❑ Scientific Advisory Council, Breast International Group (BIG), Committee Member (2011-Present)
- ❑ Institut National du Cancer, INCa, Scientific Committee Member (2010-Present)
- ❑ European Society for Medical Oncology, Metastatic Breast Cancer, Scientific Committee Member (2011-Present)



- ❑ European Organization for Research and Treatment of Cancer (EORTC), Breast Cancer Study Group, Member (2011 – present)
- ❑ Komen Scholar Scientific Peer Review Committee (2011-2012)
- ❑ Member of Breast International Group and North American Breast Cancer Group partnership under coordination of the National Cancer Institute (2009-Present)
- ❑ European Society for Medical Oncology, Metastatic Breast Cancer, Scientific Committee Chair (2014)
- ❑ European Society for Medical Oncology, IMPAKT meeting, Scientific Committee Chair (2014)
- ❑ European Society for Medical Oncology Press & Media Affairs Committee member, Official Spokesman for Breast Cancer (2014-Present)
- ❑ European Society of Oncology, Women for Oncology Committee member (2014-Present)
- ❑ European Society of Oncology, Global Policy Committee member (2015-Present)
- ❑ European Society of Oncology, Membership Committee member (2015-Present)
- ❑ St Gallen Oncology Conference on Treatment of Early Breast Cancer 2017, Conference Scientific Chair.

## CLINICAL AND SCIENTIFIC LEADERSHIP

---

Giuseppe Curigliano, MD, PhD, is of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, where besides his clinical work. He is a clinician and researcher specializing in breast cancer. Dr. Curigliano earned his MD at the Università Cattolica del Sacro Cuore, in Rome, Italy. He also holds a PhD in clinical pharmacology from the University of Pisa. He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993-1994) working on clinical immunology studies in solid tumors. He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995-96). This working experience was concentrated on molecular epidemiology studies related to carcinogen-DNA adducts, susceptibility genes characterization in solid tumors; gene-environment interactions and development of monoclonal antibodies for carcinogen DNA-adducts detection. He moved to the European Institute of Oncology in 1999. He applied to clinical research his strong basic science background leading several translational research protocols on breast and urogenital cancer. He was committed for 5 years in the phase I unit, contributing to successful development of several targeted agents and cytotoxics. Since 2001 he is adjunct professor of Clinical Pharmacology at University of Milan, concentrating his lectures on clinical pharmacology of anticancer biologicals and cytotoxics. In 2010 he visited Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. He is co-chair of Division

of Clinical Oncology coordinating clinical and comprehensive management of patients with all solid tumors (lung, gastrointestinal, urogenital, breast, soft tissue sarcomas and rare tumors). He is an active member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the Associazione Italiana di Oncologia Medica (AIOM). He is founding member of/and scientific coordinator for the International Cardio-Oncology Society (ICOS). He serves on the Clinical Research Committee of the AIOM. He serves as faculty member in the European School of Oncology (ESO). He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group (BIG). He is ESMO and ESO Faculty Member for Breast Cancer. He served on the Program Scientific Committee of ESMO 2012 and 2013. He served on the Program Scientific Committee of the St Gallen conference 2009, 2011 and 2013 as scientific secretary. Since October 2011 to May 2012 he served as a Susan G. Komen for the Cure Scholar. He served on the Program Scientific and Executive Committees of the IMPAKT Breast Cancer Conference from 2011 to 2015.

Dr. Curigliano's research experiences include principle or coinvestigator work in several phase I-II clinical trials with targeted agents, cytotoxic and endocrine agents in breast cancer. He has been also involved as principal investigator in several phase I studies with peptide vaccines for breast cancer (either in the adjuvant either in the metastatic setting). Dr Curigliano's research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the coordinator of a research platform on new drug development at European Institute of Oncology. Dr. Curigliano has written widely on oncology, including articles in the Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer (more than 180 peer reviewed article, most of them as first author) and several book chapters. He also reviews for a number of journals, including the Journal of Clinical Oncology, Annals of Oncology, the Journal of the National Cancer Institute and the European Journal of Cancer. He is member of the editorial board of Annals of Oncology, Journal of Clinical Oncology and Cancer Treatment reviews.

## **TRANSLATIONAL CANCER RESEARCH**

---

There is a major trend of importance in the oncology field. The growing importance of translational science in oncology care is the actual milestone. Increasingly, our treatment decisions and therapies are being guided by advanced biological insights from molecular and cellular biology and bioinformatics. I hold an undergraduate degree in molecular biology and a PhD in Clinical Pharmacology, and I still find it challenging to stay abreast of these fantastic developments. All my early and actual working activity is within clinical trials with strong translational research. We must continue helping oncologists and clinical investigators understand the science of cancer care through scientific symposia and educational programs. The future of cutting-edge cancer treatments will depend on such understanding. Through its meetings, educational programs, grants, guidelines, publications, and online media, we must bring to the oncology community scientific insights that allow patients and clinicians to engage in 21st century oncology. I established a phase I-II Trials Unit at European Institute of Oncology using the facilities of the IEO Translational Research Campus. I obtained several

research grants in clinical translational immunology (mechanisms of resistance to anti-HER2 therapies) and in translational cancer research. I am actually involved as principal investigator in a translational trial committed to develop xenograft models. The experimental plan to achieve this objective will contemplate several intermediate endpoints: i) generation of primary human breast xenografts using the above mentioned cohort of patients, ii) set up of in vivo RNAi screening using cells from primary xenografts as cancer cells in the assay, and iii) whole exome sequencing of primary tumor samples, primary xenografts and secondary tumors obtained from RNAi screening. Identification of molecular events by exome sequencing tools in tumor xenografts obtained from collected tumor tissues, may be crucial to understand molecular mechanisms inducing resistance to first line therapy. I am also committed in a national grant research protocol on stem cell research. I am also the PI of the TRANSCAN project on the prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer. The development of surrogates for drug efficacy is becoming a major challenge in clinical research. Such surrogates could dramatically speed-up drug development by allowing quick selection of successful compounds, avoiding large adjuvant trials and identifying patients at very good outcome. In breast cancer, pathological complete response (pCR) and Ki67 drops have been proposed as surrogates for the efficacy of chemotherapy and endocrine therapy. FDA recently proposed the use of pCR for drug approval, emphasizing the need for research in this field. Preclinical studies have suggested that cytotoxic agents may partly exert their antitumor activity by inducing immune response against tumor cells. The immunogenic cell death induced by cytotoxic agents allows antigen cross-presentation, activation of dendritic cells and induction of tumor-specific cytotoxic T cells. A few studies on small breast cancer series have suggested that cytotoxic agents, including anthracyclines and taxanes, can induce tumor-specific immune response, and that exposure to such drugs could lead to the attraction of lymphocytes in the tumor bed. With the aim to identify a new potential tool for a better selection of high-risk patients eligible for postneoadjuvant investigational drugs and that could also represent a new surrogate for neoadjuvant drug efficacy for TNBC, we are evaluating whether the magnitude of lymphocytic infiltration in the residual disease after NACT could allow identifying a population of TNBC patients at good outcome. We are also assessing expression of cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), the programmed death 1 (PD-1) receptor and its two known ligands, PD-L1 (also known as B7-H1 or CD274) and PD-L2 (also known as B7-DC or CD273). I'm actually the PI of the first trial on precision medicine in metastatic breast cancer (trial fully supported by Italian Association for Cancer Research).

## ORGANISATIONAL LEADERSHIP

---

### **Academic**

**European Institute of Oncology:** I played a significant role in establishing an educational program in Milan and leading its development to one of the largest and best funded academic programs in Italy. I was committed for 10 years in providing a yearly "Clinical Science in Oncology Seminars" program. Aims of the Seminars are to review developments in specific

topics of oncology and to keep practicing physicians up to date with recent research and opinion. Global opinion leaders took part to these seminars.

University of Milan: In the last 7 years I was actively involved in the educational program of the Master of Clinical Pharmacology in Cancer Therapy, University of Milan, providing post-graduate

In 2014 I obtained the National Academic Qualification as Associate Professor (2013-2017)

## **INTERACTION WITH INDUSTRY**

---

I have established board level links with a number of global pharmaceutical and healthcare companies which has led to significant grant funding (GlaxoSmithKline, Roche, Pfizer, Sanofi-Aventis, Novartis, Millenium Takeda, Philogen).

IEO has an impressive record of protecting and developing its IPR and establishing spin out companies. When working at IEO, I established one of their first biotechnology spin outs in collaboration with Institute Goustave Roussy in Paris.

## **INTERNATIONAL COLLABORATIONS:**

---

**USA** I have established a series of collaborations with the USA's major cancer research centres (North American Breast Cancer Group, National Cancer Institute, MD Anderson, Memorial Sloan Kettering and Dana Farber, Harvard).

**INDIA** As a member of the scientific advisory board of the BIG and ESMO, I'm actively involved in the "Developing Countries Task Force", aimed to develop academic clinical research within a network of India's top cancer centres, in partnership with BIG. This collaboration will provide training opportunities for Indian investigators in Europe and will build an internationally competitive clinical research network.

**EUROPE** I had the opportunity to collaborate within the BIG network with all centres of excellence for clinical cancer research in Europe. I am in a strong position to improve standing of Medical Oncology in Europe.

**SOUTH AMERICA** I have established active collaboration with Brasil and Argentina institution training and mentoring clinician scientist that visited my institution in Milan.

**NORTH AFRICA** I have been involved in a collaborative clinical network of cancer research centres in Libia and Egypt (involving scientist with education and training in European and US countries).

## **RESEARCH GRANTS RECEIVED**

---

### **1994**

- Toniolo Institute Grant - E 15,000.  
One year's salary for Research Assistant  
Grant Holder: G. Curigliano

### **1995-1998**

- Fondazione Italiana per la Ricerca sul Cancro (FIRC) Triennial Grant – E 150,000  
Molecular biology of transitional cell bladder carcinoma. Research Grant  
Grant Holder: G. Curigliano

### **1999-2001**

- Ricerca Finalizzata Ministero della Salute Grant – E 110,000  
2 year salary for senior post-doctoral scientist for project on pharmacogenetics of transitional bladder cell carcinoma  
Grant Holder: G. Curigliano

### **2001-2009**

- Associazione Italiana Ricerca sul Cancro Grant - E 150,000  
2 year's salary for senior post-doctoral scientist for project on identification of gene signature predictive of response to bevacizumab in triple negative breast cancer Grant Holders – A. Goldhirsch, G. Curigliano
- Ricerca Finalizzata Ministero della Salute Grant - E 210,000  
Identification of Mechanisms of resistance to trastuzumab  
Grant Holders – M. Rescigno, G Curigliano
- Cariplo Foundation Grant- E 60,000  
Eps8 gene polymorphism and toxicity from cisplatin  
Grant Holders – N. Offenhauser, G. Curigliano

- Umberto Veronesi Foundation Grant – E 120,000  
Role of cancer stem cells in anticancer drug resistance  
Grant Holder – G. Bonizzi, G. Curigliano

#### **2009-2011**

- Roche Unrestricted Grant- E 300.000  
To explore activity of bevacizumab in lymphangitic breast cancer  
Grant holders – A. Goldhirsch, G. Curigliano

#### **2011-2012**

- Umberto Veronesi Foundation Grant E 200,000  
Genome Remodeling in Luminal B, HER2 and Ductal Triple Negative Breast Cancer Metastasis and Xenograft: Exome sequencing analysis for identification of driver pathways to overcome resistance  
Grant holder – G. Curigliano
- Career Catalyst Research (CCR) Komen Grant E. 450.000  
Measuring Estrogen Levels During Letrozole Interruption – The SOLE-EST Substudy  
Grant holders – A. Goldhirsch, G. Curigliano
- Associazione Italiana Ricerca sul Cancro (AIRC) Grant E 3,000,000  
Understanding how cancer stem cells drive breast cancer growth and how to exploit them as its Achilles' heel  
Task 5 Team Leader: G Curigliano  
Optimization of available therapies: Breast cancer stem cells and drug resistance  
Grant Holders: P.P. Di Fiore, P.G. Pelicci, G. Viale and A. Goldhirsch

#### **2012-2015**

- ERA-Net on translational cancer research (TRANSCAN) E 3.000,000  
"CD3 and CD20 lymphocytes infiltration to predict chemosensitivity in patients with triple negative breast cancer", UGI1  
Grant holder – F. Andrè, G. Curigliano, K. Denkert

#### **2015-2017**

- AIRC funding on translational cancer research E 300.000  
" Clinical utility of a next generation sequencing-based "oncochip" for therapeutic decision in metastatic breast cancer"  
Grant holder –G. Curigliano

#### **2015-2017**

Ministero della Salute Funding Euros 360.000

“ Master protocol of precision medicine for treatment of metastatic breast cancer”

Grant holder –G. Curigliano

## **PUBLICATIONS**

---

### **PUBLISHED ABSTRACTS**

Over 800 abstracts presented at national and international conferences.


### **THESES and MENTORING**

Dr Curigliano was committed in the last 15 years to training and mentoring medical student, residents and PhD students. He provided excellence in undergraduate, postgraduate and continuing medical education.


MD	4-ABP DNA adducts in transitional cell carcinoma of the bladder
	dHER2 peptide vaccine ad adjuvant therapy in HER2 positive breast cancer
	Pharmacogenetic determinants of response to intravesical gemcitabine in transitional cell carcinoma of the bladder stage pT1, pT1
	Identification of a gene signature predictive of response to bevacizumab in lymphangitic breast cancer
	Cancer testis antigens expression in triple negative breast cancer
PhD	Pharmacogenetic determinants of response to intravesical gemcitabine in transitional cell carcinoma of the bladder stage pT1, pT1
MD	Xenograft models in breast cancer subtypes

## **BIBLIOMETRIC DATA**

### Published Items in each year



### Citations in Each Year



Thompson Reuters: **H index: 35**

Google Scholar: **H index 70**

Total **IF points: 1534,70**

Sum of the Times Cited: 3724

Sum of Times Cited without self-citations: 3611

Citing Articles: 3436

Citing Articles without self-citations: 3369

Average Citations per Item : 11.63

**Top Italian Scientist Biomedical Science**

Ranked 52, H Index 70



52	<a href="#">Giuseppe Curigliano</a>	70	Italy	cancer - medicine	Biomedical Sciences	IEO Milano	<a href="#">Verified Google Scholar MyCitations</a>
----	-------------------------------------	----	-------	-------------------	---------------------	------------	---

## PEER REVIEWED PUBLICATIONS

- 1) F. Wolf, D. Bossi, G. Calviello, A. Romito, **G. Curigliano**, L. Lauro and A. Cittadini. Effect of Magnesium on tumor cells metabolism. *Acta Medica Romana* 30, 3: 109-116, (1992).
- 2) D. Bossi, F. Wolf, G. Calviello, L. Lauro, **G. Curigliano**, A. Romito and A. Cittadini. Magnesium in the regulation of ascites tumor cell energy metabolism. *Molecular Oncology And Clinical Application* (Birkhauser, Basel). Edited by A. Cittadini, R. Baserga, H.M. Pinedo, T. Galeotti and D. Corda (1993).
- 3) G. Flamini, C. Ratto, G. Ferretti, M. Genuardi, P. Nucera, L. Sofo, **G. Curigliano**, A. Sgambato, G.B. Doglietto, D. Bossi, F. Crucitti and A. Cittadini. Kras oncogene mutations in the stool in patients with colorectal cancer. *Acta Medica Romana* 32, 4: 411-417, (1994).
- 4) G. Flamini, M. Giustacchini, E. Alcini, C. Ratto, G. Calvisi, A. Astone, T. Ventura, A. D'Addessi, **G. Curigliano**, G. Ferretti, M. Racioppi, A. Alcini, A. Sgambato, A. Cittadini and F. Crucitti. Immunohistochemical study of p53 in urinary bladder cancer. *Acta Medica Romana* 32, 4: 405-410, (1994).
- 5) G. Flamini, **G. Curigliano**, C. Ratto, A. Astone, G. Ferretti, P. Nucera, L. Sofo, A. Sgambato, F. Crucitti and A. Cittadini. Prognostic significance of cytoplasmic p53 overexpression in colorectal cancer. An Immunohistochemical study. *European Journal of Cancer*, 32A, 5: 802-806 (1996).
- 6) **G. Curigliano**, Y.J. Zhang, L.Y. Wang, G. Flamini, A. Alcini, C. Ratto, M. Giustacchini, E. Alcini, A. Cittadini and R.M. Santella. Immunohistochemical quantitation of 4-aminobiphenyl(ABP)-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. *Carcinogenesis*, 17, 5: 911-916, (1996).
- 7) C. Ratto, G. Flamini, L. Sofo, P. Nucera, M. Ippoliti, **G. Curigliano**, G. Ferretti, A. Sgambato, M. Merico, G.B. Doglietto, A. Cittadini and F. Crucitti. Detection of ras oncogene mutations from neoplastic cells exfoliated in feces. *Disease of the Colon Rectum*, 39: 1238-1244, (1996).
- 8) G. Flamini, M. Giovagnoli, **G. Curigliano**, G. Romano, R. Mancini, A. Boninsegna, A. Vecchione, R.M. Santella and A. Cittadini. Immunohistochemical quantitation of 4-aminobiphenyl(ABP)-DNA adducts in oral mucosa cells of smokers and nonsmokers. *Cancer Detection and Prevention*, 20, 5: 416, (1996).
- 9) G. Romano, R. Mancini, P. Fedele, **G. Curigliano**, G. Flamini, M.R. Giovagnoli, N. Malara, A. Boninsegna, A. Vecchione, R. Santella and A. Cittadini. Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts in oral mucosa cells of smokers and nonsmokers. *Anticancer Research* 17: 2827-2830, (1997).
- 10) G. Flamini, S. Magalini, **G. Curigliano**, G. Nanni, A. Boninsegna, S. Agnes, D. Faticato, M. Castagneto and A. Cittadini. Immunohistochemical analysis of p53 protein in transplant

recipients with Kaposi's sarcoma. *Journal of Cancer Research and Clinical Oncology* 123: 240-242, (1997).

11) **G. Curigliano**, A. Alcini, G. Flamini, A. Boninsegna, C. Ratto, M. Giustacchini, G. Romano, E. Alcini, Y.J. Zhang, R.M. Santella and A. Cittadini. Immunohistochemical analysis of 4-aminobiphenyl-DNA adducts and p53 nuclear overexpression in T1 bladder cancer of smokers and nonsmokers. *Acta Medica Romana*, 35, 1:18-28, (1997).

12) G. Flamini, G. Romano, **G. Curigliano**, A. Chiominto, G. Capelli, A. Boninsegna, C. Signorelli, L. Ventura, R.M. Santella, A. Sgambato and A. Cittadini. 4-Aminobiphenyl-DNA adducts in laryngeal tissue and smoking habits: an immunohistochemical study. *Carcinogenesis*, 19, 2: 353-357, (1997).

13) M. Ciaparrone, D. Terribile, **G. Curigliano**, A. Marra, A. Sgambato, A. Boninsegna, R. Masetti, A. Carbone, G. Flamini, A. Picciocchi and A. Cittadini. P-170 glycoprotein (MDR) and p53 expression in breast cancer. *The Breast Journal*, 4, 4: 1-7, (1998).

14) G. Romano, A. Sgambato, A. Boninsegna, G. Flamini, **G. Curigliano**, Q. Yang, V. La Gioia, C. Signorelli, A. Ferro, G. Capelli, R.M. Santella and A. Cittadini. Evaluation of polycyclic aromatic hydrocarbons DNA adducts in exfoliated oral cells by an immunohistochemical assay. *Cancer Epidemiology, Biomarkers & Prevention.*, Jan.. 8 (1): 91-6, (1999).

15) Romano G, Garagnani L, Boninsegna A, Ferrari P, Flamini G, De Gaetani C, Sgambato A, Giovanni F, **Curigliano G**, Ferretti G, Cittadini A, Trentini G. Analysis of 4-ABP-DNA adducts and p53 alterations in urinary bladder carcinoma. *Anticancer Research Sep-Oct;19(5C):4571-6*, (1999).

16) Orlando L, Colleoni M, Nole F, Biffi R, Rocca A, **Curigliano G**, Ferretti G, Peruzzotti G, de Braud F, Masci G, Goldhirsch Incidence of venous thromboembolism in breast cancer patients during chemotherapy with vinorelbine, cisplatin, 5-fluorouracil as continuous infusion (ViFuP regimen): is prophylaxis required? *A. Annals of Oncology. Jan;11(1):117-8*, (2000).

17) De Pas T, **Curigliano G**, Catania C, Comandone A, de Braud F. Ifosfamide in the elderly: clinical considerations for a better drug management. *Critical Review in Oncology Hematology. Feb;33(2):129-35*, (2000). Review.

18) De Pas TM, Mandala M, **Curigliano G**, Peccatori F. Acute vulvar vestibulitis occurring during chemotherapy with cryptophycin analogue LY355703. *Obstetrics & Gynecology. Jun 1;95(6 Suppl 1):1030*, (2000).

19) Ferretti G. & **Curigliano G.**, Pastorino U., Cittadini A., Flamini G., Calabrò M.G., De Pas T., Orlando L., Mandalà M., Spaggiari L., Granone P., Pagliari G., Fazio N. and Goldhirsch A.. Detection by Denaturant Gradient Gel Electrophoresis of tumor specific mutations in biopsies and relative bronchoalveolar lavage fluid from resectable non-small cell lung cancer. *Clinical Cancer Research*, 6, 6: 2393-2401, (2000).

20) De Pas T., de Braud F., Danesi R., Sessa C., Catania C., **Curigliano G.**, Fogli S., del Tacca M., Zampino G., Sbanotto A., Cinieri S., Marrocco E., Milani A. and Goldhirsch A.. Phase I and pharmacologic study of weekly Gemcitabine and Paclitaxel in chemo-naïve patients with advanced non-small cell lung cancer. *Annals of Oncology*, 11: 821-827, (2000)

21) De Pas T., de Braud F., Mandalà M., **Curigliano G.**, Catania C., Ferretti G., Sozzi P., Solli P. and Goldhirsch A.. Cisplatin and Vinorelbine as second-line chemotherapy in patients with advanced non-small cell lung cancer resistant to taxol plus gemcitabine. *Lung Cancer*, 2001 Feb-Mar;31(2-3):267-70.

22) M. Colleoni, I. Minchella, G. Mazzarol, F. Nolè, G. Peruzzotti, A. Rocca, G. Viale, L. Orlando, G. Ferretti, **G. Curigliano**, P. Veronesi, M. Intra and A. Goldhirsch. Response to

primary chemotherapy in breast cancer patients with tumors non expressing estrogen and progesteron receptors. *Annals of Oncology*, August 11, 1057-1059, 2000

23) P. Lissoni, M. Mandalà, **G. Curigliano**, G. Ferretti and S. Barni. A progress report on the palliative therapy of 100 patients with neoplastic effusions by intracavitary low-dose interleukin-2. *Oncology*, 2001;60(4):308-12.

24) M. Mandalà, C. Moro, G. Ferretti, M.G. Calabrò, F. Nolè, A. Rocca, E. Munzone, A. Castro and **G. Curigliano**. Effect of Tamoxifen on GH and IGF-1 serum level in stage I-II breast cancer patients. *Anticancer Research*. 2001 Jan-Feb;21(1B):585-8.

25) **G. Curigliano**, G. Ferretti, Calabrò M.G. et Al. GST-M1, p53 and K-ras molecular detection in resectable NSCLC by DGGE bronchoalveolar lavage fluid analysis. Accepted by *Anticancer Research*

26) **G. Curigliano**, G. Ferretti, Calabrò M.G. et Al. Diagnosis of T1 bladder transitional cell carcinoma by DGGE urinalysis. Accepted by *Anticancer Research*.

27) **G. Curigliano**, G. Ferretti, M. Colleoni et Al. Bone scan had no role in the staging of 765 consecutive operable T1-2 N0-1 breast cancer patients without skeletal symptoms. *Annals of Oncology*, 2001 May;12(5):724-5.

28) **G. Curigliano** and G. Ferretti. *Oncogenesi. Trattato di Radioterapia*.

29) **Curigliano G**, Ferretti G, Colleoni M, Marrocco E, Peruzzotti G, De Cicco C, Paganelli G, Goldhirsch A. Bone scan had no role in the staging of 765 consecutive operable T(1-2)N(0-1) breast cancer patients without skeletal symptoms. *Ann Oncol* 2001 May;12(5):724-5

30) **Curigliano G**, Ferretti G, Flamini G, Goldhirsch A, de Braud F, Calabro MG, Mandaly M, Nole F, De Pas T, D'Addessi A, Cittadini A. Diagnosis of T1 bladder transitional cell carcinoma by denaturing gradient gel electrophoresis urinalysis. *Anticancer Res* 2001 Jul-Aug;21(4B):3015-20

31) De Pas T, **Curigliano G**, Franceschelli L, Catania C, Spaggiari L, de Braud F. Gemcitabine-induced systemic capillary leak syndrome. *Ann Oncol* 2001 Nov;12(11):1651-2

32) Curigliano G, Ferretti G, Mandala M, De Pas T, Calabro MG, Solli P, Noberasco C, de Braud F. GSTM1, P53 and K-ras molecular detection in resectable non-small cell lung cancer by denaturing gradient gel electrophoresis-bronchoalveolar lavage fluid analysis. *Anticancer Res* 2001 Sep-Oct;21(5):3461-9

33) Orlando L., Colleoni M., **Curigliano G**. et al. Chemotherapy with vinorelbine, cisplatin and continuous infusion of 5-fluorouracil in locally advanced breast cancer: a promising low-toxic regimen. *Anticancer Res*. 2001 Nov-Dec;21(6A):4135-9.

34) De Pas T, **Curigliano G**, Masci G, Catania C, Comandone A, Boni C, Tucci A, Pagani O, Marrocco E, de BF; Italian Sarcoma Group. Phase I study of twelve-day prolonged infusion of high-dose ifosfamide and doxorubicin as first-line chemotherapy in adult patients with advanced soft tissue sarcomas. *Ann Oncol* 2002 Jan;13(1):161-6

35) S. Fogli, R. Danesi, F. de Braud, T. De Pas, **G. Curigliano** et al. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with NSCLC. *Ann Oncol* 12: 1553-1559, 2001

36) **Curigliano G**, Mandala M, Minchella I, Goldhirsch A. Mediastinal lymphadenopathy in a patient with breast cancer. *Lancet Oncol* 2002 Mar;3(3)

37) **G. Curigliano**, M. Colleoni, G. Renne, G. Mazzarol et Al. Recognizing features that are dissimilar in male and female breast cancer: expression of p21Waf1 and p27Kip1 using an immunohistochemical assay. *Ann Oncol*. 2002 Jun;13(6):895-902.

- 38) De Pas T. , Pastorino U., Spaggiari L., **Curigliano G.** et al Preoperative chemotherapy in non-small-cell lung cancer: nothing new in N2 disease. *J Clin Oncol.* 2002 May 15;20(10):2603-4
- 39) Mandala M, Lissoni P, Ferretti G, Rocca A, Torri V, Moro C, **Curigliano G**, Barni S. Postoperative hyperprolactinemia could predict longer disease-free and overall survival in node-negative breast cancer patients. *Oncology.* 2002;63(4):370-7.
- 40) Ferretti G, Mandala M, Di Cosimo S, Moro C, **Curigliano G**, Barni S. Catheter-related bloodstream infections, part I: pathogenesis, diagnosis, and management. *Cancer Control.* 2002 Nov-Dec;9(6):513-23.
- 41) Orlando L, **Curigliano G**, Colleoni M, Fazio N, Nole F, Martinelli G, Cinieri S, Graffeo R, Peruzzotti G, Goldhirsch A. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. *Anticancer Res.* 2002 Sep-Oct;22(5):3057-9.
- 42) Veronesi G, Spaggiari L, De Pas T, Solli PG, De Braud F, Catalano GP, **Curigliano G**, Leo F, Pastorino U. Preoperative chemotherapy is essential for conservative surgery of Askin tumors. *J Thorac Cardiovasc Surg.* 2003 Feb;125(2):428-9.
- 43) Ferretti G, Mandala M, Di Cosimo S, Moro C, **Curigliano G**, Barni S. Catheter-related bloodstream infections, part II: specific pathogens and prevention. *Cancer Control.* 2003 Jan-Feb;10(1):79-91.
- 44) Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G, Del Tacca M. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. *Pharmacol Rev.* 2003 Mar;55(1):57-103.
- 45) Di Cosimo S, Pistillucci G, Ferretti G, Cicchetti A, Leggio M, Silvestris N, Moro C, Mandala M, **Curigliano G**, Battigaglia B, Di Chio G, Cirignotta S, D'Aprile M. Palliative home care and cost savings: encouraging results from Italy. *N Z Med J.* 2003 Mar 14;116(1170):U370.
- 46) Di Cosimo S, Ferretti G, Fazio N, Mandala M, **Curigliano G**, Bosari S, Intra M, Latronico A, Goldhirsch A. Breast and ovarian metastatic localization of signet-ring cell gastric carcinoma. *Ann Oncol.* 2003 May;14(5):803-4.
- 47) Solli P, Leo F, Veronesi G, Curigliano G, Martinoni A, Spaggiari L, Cipolla C, Pastorino U. Impact of limited pulmonary function on the management of resectable lung cancer. *Lung Cancer.* 2003 Jul;41(1):71-9.
- 48) Colleoni M, **Curigliano G**, Minchella I, Peruzzotti G, Nole F, Mazzarol G, Renne G, Orlando L, Rocca A, Veronesi P, Intra M, Viale G, Sandri MT, Severi G, Goldhirsch A. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. *Ann Oncol.* 2003 Oct;14(10):1477-83.
- 49) De Pas T, Danesi R, Catania C, **Curigliano G**, De Braud F; Italia Sarcoma Group. Imatinib administration in two patients with liver metastases from GIST and severe jaundice. *Br J Cancer.* 2003 Oct 20;89(8):1403-4.
- 50) Mandala M, Ferretti G, Cremonesi M, Cazzaniga M, **Curigliano G**, Barni S. Venous thromboembolism and cancer: new issues for an old topic. *Crit Rev Oncol Hematol.* 2003 Oct;48(1):65-80.
- 51) Fazio N, Orsi F, Grasso RF, Ferretti G, Medici M, Rocca A, Zampino G, **Curigliano G**, De Pas T, Colleoni M, Bonomo G, Marrocco E, Lunghi L, De Braud F. Hepatic intra-arterial chemotherapy using a percutaneous catheter in pretreated patients with metastatic colorectal carcinoma.

Anticancer Res. 2003 Nov-Dec;23(6D):5023-30.

52) Gennari R, **Curigliano G**, Jerezek-Fossa BA, Zurrída S, Renne G, Intra M, Galimberti V, Luini A, Orecchia R, Viale G, Goldhirsch A, Veronesi U. Male breast cancer: a special therapeutic problem. Anything new? *Int J Oncol.* 2004 Mar;24(3):663-70.

53) Mandala M, **Curigliano G**, Bucciarelli P, Ferretti G, Mannucci PM, Colleoni M, Ventura A, Peruzzotti G, Severi G, Pelicci PG, Biffi R, Orsi F, Cinieri S, Goldhirsch A. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. *Ann Oncol.* 2004 Apr;15(4):590-3.

54) **Curigliano G**, Cipolla C, de Braud F. Drug-induced prolongation of the QT interval. *N Engl J Med.* 2004 Jun 17;350(25):2618-21

55) **Curigliano G**, Rigo R, Colleoni M, Braud FD, Nole F, Formica V, Orlando L, Cinieri S, Torrisi R, Cardillo A, Peruzzotti G, Medici M, Ardito R, Minchella I, Goldhirsch A. Adjuvant therapy for very young women with breast cancer: response according to biologic and endocrine features. *Clin Breast Cancer.* 2004 Jun;5(2):125-30.

56) Gennari R, **Curigliano G**, Rotmensz N, Robertson C, Colleoni M, Zurrída S, Nole F, de Braud F, Orlando L, Leonardi MC, Galimberti V, Intra M, Veronesi P, Renne G, Cinieri S, Audisio RA, Luini A, Orecchia R, Viale G, Goldhirsch A. Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients. *Cancer.* 2004 Sep 15;101(6):1302-10.

57) Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, **Curigliano G**, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nole F, Peruzzotti G, Goldhirsch A. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. *Clin Cancer Res.* 2004 Oct 1;10(19):6622-8.

58) Fazio N, De Pas T, de Braud F, Spaggiari L, Mazzarol G, Biffi R, Andreoni B, Zampino M, **Curigliano G**, Lorizzo K, Di Meglio G, Goldhirsch A. CDX-2 should be included in the work-up of patients with lung metastases from unknown primary. *Ann Oncol.* 2004 Dec;15(12):1850.

59) De Pas T, **Curigliano G**, Veronesi G, Catalano G, Catania C, Jerezek-Fossa B, Orecchia R, Spaggiari L, de Braud F. Optimization of the schedule of gemcitabine-cisplatin combination as induction regimen for patients with biopsy-proven stage IIIa N2 - stage IIIb non-small-cell lung cancer: a prospective phase-II study. *Bull Cancer.* 2004 Sep 1;91(9):E273-7.

60) De Pas T, Pelosi G, de Braud F, Veronesi G, **Curigliano G**, Leon ME, Danesi R, Noberasco C, d'Aiuto M, Catalano G, Viale G, Spaggiari L. Modulation of epidermal growth factor receptor status by chemotherapy in patients with locally advanced non-small-cell lung cancer is rare. *J Clin Oncol.* 2004 Dec 15;22(24):4966-70.

61) Noberasco C, De Pas T, **Curigliano G**, Manzoni S, Dodaro L, Pelosi G, Spaggiari L, De Braud F. Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer? *J Clin Oncol.* 2005 Feb 1;23(4):921-2.

62) De Pas T, Colleoni M, Orlando L, Masci G, Rocca A, Catania C, **Curigliano G**, Manzoni S, Goldhirsch A, de Braud F. Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity: ... and in humans? *Ann Oncol.* 2005 Apr;16(4):673.

63) De Pas T, Sbanotto A, Catania C, Banfi MG, **Curigliano G**, Nole F, Fazio N, Formica V, Veronesi G, de Braud F. Oral administration of vinorelbine can overcome intractable endovenous-vinorelbine-associated acute tumor pain. *Support Care Cancer.* 2005 Mar;13(3):194-5.

- 64) de Braud F, De Pas T, Spaggiari L, Veronesi G, **Curigliano G**, Noberasco C, Pelosi G. Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. *J Natl Cancer Inst.* 2005 Mar 16;97(6):461-2
- 65) Sessa C, De Braud F, Perotti A, Bauer J, **Curigliano G**, Noberasco C, Zanaboni F, Gianni L, Marsoni S, Jimeno J, D'Incalci M, Dall'o E, Colombo N. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. *J Clin Oncol.* 2005 Mar 20;23(9):1867-74.
- 66) Orlando L, Renne G, Rocca A, **Curigliano G**, Colleoni M, Severi G, Peruzzotti G, Cinieri S, Viale G, Sanna G, Goldhirsch A. Are all high-grade breast cancers with no steroid receptor hormone expression alike? The special case of the medullary phenotype. *Ann Oncol.* 2005 Jul;16(7):1094-9. Epub 2005 Apr 26.
- 67) De Pas T, Putzu C, Pelosi G, **Curigliano G**, Noberasco C, Zampino G, Fazio N, Formica V, Spaggiari L, de Braud F. Target-treatment and patients' selection: can we still neglect the timing of tissue collection? *J Clin Oncol.* 2005 Sep 1;23(25):6274-5
- 68) **Curigliano G**, Petit JY, Bertolini F, Colleoni M, Peruzzotti G, de Braud F, Gandini S, Giraldo A, Martella S, Orlando L, Munzone E, Pietri E, Luini A, Goldhirsch A. Systemic effects of surgery: quantitative analysis of circulating basic fibroblast growth factor (bFGF), Vascular endothelial growth factor (VEGF) and transforming growth factor beta (TGF-beta) in patients with breast cancer who underwent limited or extended surgery. *Breast Cancer Res Treat.* 2005 Sep;93(1):35-40.
- 69) **Curigliano G**, Colleoni M, Mandala M, De Pas T, Spitaleri G, de Braud F, Goldhirsch A. Prophylaxis for venous thromboembolism in cancer patients with a central vein catheter: new tones for an old song. *J Clin Oncol.* 2005 Oct 1;23(28):7243-4
- 70) **Curigliano G**, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A, Munzone E, Rocca A, Bonizzi G, Brichard V, Orlando L, Goldhirsch A. Breast cancer vaccines: a clinical reality or fairy tale? *Ann Oncol.* 2006 May;17(5):750-62
- 71) **Curigliano G**, Formica V, De Pas T, Spitaleri G, Pietri E, Fazio N, de Braud F, Goldhirsch A. Life-threatening toxic epidermal necrolysis during voriconazole therapy for invasive aspergillosis after chemotherapy. *Ann Oncol.* 2006 Jul;17(7):1174-5.
- 72) Munzone E, **Curigliano G**, Rocca A, Bonizzi G, Renne G, Goldhirsch A, Nole F. Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy. *Breast Cancer Res.* 2006;8(1):R4
- 73) **Curigliano G**, Magni E, Renne G, De Cobelli O, Rescigno M, Torrisci R, Spitaleri G, Pietri E, De Braud F, Goldhirsch A. Burned out" phenomenon of the testis in retroperitoneal seminoma. *Acta Oncol.* 2006;45(3):335-6.
- 74) Zampino MG, Verri E, Locatelli M, **Curigliano G**, Ascione G, Sbanotto A, Rocca A, Verweij F, Matei V, Scardino E, Decobelli O, Goldhirsch A, Nole F. Vinorelbine-based chemotherapy in hormone-refractory prostate cancer. *Anticancer Res.* 2006 May-Jun;26(3B):2375-80.
- 75) Mey V, Giovannetti E, De Braud F, Nannizzi S, **Curigliano G**, Verweij F, De Cobelli O, Pece S, Del Tacca M, Danesi R. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. *Br J Cancer.* 2006 Aug 7;95(3):289-97
- 76) De Pas T, Putzu C, **Curigliano G**, Noberasco C, Sabrina B, Catania C, Orlando L, Milani A, Spaggiari L, de Braud F. A proper schedule of weekly paclitaxel and gemcitabine combination is highly active and very well tolerated in NSCLC patients. *Lung Cancer.* 2006 Dec;54(3):359-64

- 77) Rocca A, Peruzzotti G, Ghisini R, Viale G, Veronesi P, Luini A, Intra M, Pietri E, **Curigliano G**, Giovanardi F, Maisonneuve P, Goldhirsch A, Colleoni M. A randomized phase II trial comparing preoperative plus perioperative chemotherapy with preoperative chemotherapy in patients with locally advanced breast cancer. *Anticancer Drugs*. 2006 Nov;17(10):1201-9.
- 78) **Curigliano G**, Spitaleri G, Zampino G. Treatment of rectal cancer. *N Engl J Med*. 2006 Dec 7;355(23):2487
- 79) **Curigliano G**, Pelosi G, De Pas T, Renne G, De Cobelli O, Manzotti M, Spitaleri G, de Braud F. Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib. *Prostate*. 2007 May 1;67(6):603-4.
- 80) **Curigliano G**, Balduzzi A, Cardillo A, Ghisini R, Peruzzotti G, Orlando L, Torrì R, Dellapasqua S, Lunghi L, Goldhirsch A, Colleoni M. Low-dose aspirin for the prevention of venous thromboembolism in breast cancer patients treated with infusional chemotherapy after insertion of central vein catheter. *Support Care Cancer*. 2007 Oct;15(10):1213-7
- 81) **Curigliano G**, Goldhirsch A. To switch or not to switch: implications of sequencing adjuvant endocrine therapy in patients with breast cancer. *Nat Clin Pract Oncol*. 2007 Sep;4(9):510-1.
- 82) Leo F, De Pas T, Catalano G, Piperno G, **Curigliano G**, Solli P, Veronesi G, Petrella F, Spaggiari L. Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non small-cell lung cancer. *J Natl Cancer Inst*. 2007 Aug 1;99(15):1210
- 83) De Pas T, Spitaleri G, Pruneri G, **Curigliano G**, Noberasco C, Luini A, Andreoni B, Testori A, de Braud F. Dendritic cell sarcoma: An analytic overview of the literature and presentation of original five cases. *Crit Rev Oncol Hematol*. 2007 Jul 18.
- 84) **Curigliano G**, De Braud F, Teresa Sandri M, Renne G, Zorzino L, Scardino E, Rocco B, Spitaleri G, De Pas T, Noberasco C, Nolè F, Verweij F, Matei V, De Cobelli O. Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity. *Anticancer Drugs*. 2007 Sep;18(8):949-54.
- 85) **Curigliano G**, Rescigno M, Goldhirsch A. Immunology and breast cancer: therapeutic cancer vaccines. *Breast*. 2007 Dec;16 Suppl 2:S20-6.
- 86) Rescigno M, Avogadri F, **Curigliano G**. Challenges and prospects of immunotherapy as cancer treatment. *Biochim Biophys Acta*. 2007 Sep;1776(1):108-23
- 87) **Curigliano G**, Spitaleri G, Dettori M, Locatelli M, Scarano E, Goldhirsch A. Vaccine immunotherapy in breast cancer treatment: promising, but still early. *Expert Rev Anticancer Ther*. 2007 Sep;7(9):1225-41
- 88) **Curigliano G**, Spitaleri G, Fingert HJ, de Braud F, Sessa C, Loh E, Cipolla C, De Pas T, Goldhirsch A, Shah R. Drug-induced QTc interval prolongation: A proposal towards an efficient and safe anticancer drug development. *Eur J Cancer*. 2008 Mar;44(4):494-500.
- 89) **Curigliano G**, Balduzzi A, Goldhirsch A, Colleoni M. Daily low-dose aspirin in cancer patients with central venous catheter: new role for an old drug. *Support Care Cancer*. 2008 Mar;16(3):313-4
- 90) **Curigliano G.**, Gianluca Spitaleri, Ottavio De Cobelli, Epifanio Scardino, Alberto Sbanotto and Filippo de Braud. Health related Quality of Life (QoL) in Patients with Hormone Refractory Prostate Cancer (HRPC) receiving Gefitinib. *Urologia Internationalis*. 2009;82(2):196-202.

- 91) **G. Curigliano**, G. Spitaleri, F. Nolè et al. Cisplatin, etoposide and continuous infusion bleomycin in patients with good prognosis testicular germ cell tumors: Data of long term efficacy and toxicity. *J. Chemotherapy*, 2009 Dec;21(6):687-92.
- 92) Jereczek-Fossa BA, **Curigliano G**, Orecchia R. Systemic therapies for non-metastatic prostate cancer: review of the literature. *Onkologie*. 2009 Jun;32(6):359-63
- 93) Spitaleri G, Matei DV, **Curigliano G**, Detti S, Verweij F, Zambito S, Scardino E, Rocco B, Nolè F, Ariu L, De Pas T, de Braud F, De Cobelli O. Phase II trial of estramustine phosphate and oral etoposide in patients with hormone-refractory prostate cancer. *Ann Oncol*. 2009 Mar;20(3):498-502
- 94) De Pas T, Spitaleri G, Pelosi G, De Carlis L, Lorizzo K, Locatelli M, **Curigliano G**, Toffalorio F, Catania C, de Braud F. Erlotinib combined with cyclosporine in a liver-transplant recipient with epidermal growth factor receptor-mutated non-small cell lung cancer. *J Thorac Oncol*. 2009 Jan;4(1):138-9.
- 95) Della Vigna P, Monfardini L, Bonomo G, **Curigliano G**, Agazzi A, Bellomi M, Orsi F. Coagulation disorders in patients with cancer: nontunneled central venous catheter placement with US guidance--a single-institution retrospective analysis. *Radiology*. 2009 Oct;253(1):249-52.
- 96) Munzone E, Di Pietro A, Goldhirsch A, Minchella I, Verri E, Cossu Rocca M, Marengi C, **Curigliano G**, Radice D, Adamoli L, Nolè F. Metronomic administration of pegylated liposomal-doxorubicin in extensively pre-treated metastatic breast cancer patients: a mono-institutional case-series report. *Breast*. 2010 Feb;19(1):33-7
- 97) **Curigliano G**, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrada S, Nolè F, Goldhirsch A. Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. *J Clin Oncol*. 2009 Dec 1;27(34):5693-9.
- 98) **Curigliano G**, Locatelli M, Fumagalli L, Goldhirsch A. Immunizing against breast cancer: a new swing for an old sword. *Breast*. 2009 Oct;18 Suppl 3:S51-4.
- 99) Botteri E, Sandri MT, Bagnardi V, Munzone E, Zorzino L, Rotmensz N, Casadio C, Cassatella MC, Esposito A, **Curigliano G**, Salvatici M, Verri E, Adamoli L, Goldhirsch A, Nolè F. Modeling the relationship between circulating tumour cells number and prognosis of metastatic breast cancer. *Breast Cancer Res Treat*. 2009 Dec 6
- 100) Noberasco C, Spitaleri G, Mancuso P, Zorzino L, Radice D, Milani A, Rocca A, Bertolini F, Sandri MT, **Curigliano G**, de Pas T, Jemos C, Omodeo Salè E, Boselli S, de Braud F. Safety, tolerability and biological effects of long-term metronomic administration of non-cytotoxic anti-angiogenic agents. *Oncology*. 2009;77(6):358-65.
- 101) Orgera G, **Curigliano G**, Krokidis M, Bonomo G, Monfardini L, Della Vigna P, Zampino MG, Orsi F. High-intensity focused ultrasound effect in breast cancer nodal metastasis. *Cardiovasc Intervent Radiol*. 2010 Apr;33(2):447-9
- 102) **Curigliano G**. Personalizing medicine through personalized communication: individuality of the patient across borders and cultures. *J Natl Compr Canc Netw*. 2010 Mar;8(3):277-8
- 103) **Curigliano G**, Bagnardi V, Fumagalli L, Rotmensz N, Locatelli M, Viale G, Goldhirsch A. Treatment of small HER2 positive tumors. Reply to D. Crivellari. *J Clin Oncol*. 2010 Apr 5
- 104) Johannsen M, Spitaleri G, **Curigliano G**, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, Miller K, Berndt A, Kosmehl H, Trachsel E, Kaspar M, Lovato V, González-Iglesias R, Giovannoni L, Menssen HD, Neri D, de Braud F. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with



solid tumours and expansion into patients with advanced renal cell carcinoma. *Eur J Cancer*. 2010 Nov;46(16):2926-35.

105) **Curigliano G**, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, Neville AM, Nolè F, Rotmensz N, Goldhirsch A. Cancer-testis antigen expression in triple-negative breast cancer. *Ann Oncol*. 2011 Jan;22(1):98-103.

106) **Curigliano G**, Mayer EL, Burstein HJ, Winer EP, Goldhirsch A. Cardiac toxicity from systemic cancer therapy: a comprehensive review. *Prog Cardiovasc Dis*. 2010 Sep-Oct;53(2):94-104.

107) Farante G, Zurrida S, Galimberti V, Veronesi P, **Curigliano G**, Luini A, Goldhirsch A, Veronesi U. The management of ductal intraepithelial neoplasia (DIN): open controversies and guidelines of the Istituto Europeo di Oncologia (IEO), Milan, Italy. *Breast Cancer Res Treat*. 2011 Jul;128(2):369-78.

108) Munzone E, Nolè F, Goldhirsch A, Botteri E, Esposito A, Zorzino L, **Curigliano G**, Minchella I, Adamoli L, Cassatella MC, Casadio C, Sandri MT. Changes of HER2 status in circulating tumor cells compared with the primary tumor during treatment for advanced breast cancer. *Clin Breast Cancer*. 2010 Oct 1;10(5):392-7

109) Petralia G, Bonello L, Summers P, Preda L, Malasevski A, Raimondi S, Di Filippi R, Locatelli M, **Curigliano G**, Renne G, Bellomi M. Intraobserver and interobserver variability in the calculation of apparent diffusion coefficient (ADC) from diffusion-weighted magnetic resonance imaging (DW-MRI) of breast tumours. *Radiol Med*. 2011 Apr;116(3):466-76.

110) Lohsiriwat V, **Curigliano G**, Rietjens M, Goldhirsch A, Petit JY. Autologous fat transplantation in patients with breast cancer: "silencing" or "fueling" cancer recurrence? *Breast*. 2011 Aug;20(4):351-7.

111) **Curigliano G**, Bagnardi V, Viale G, Fumagalli L, Rotmensz N, Aurilio G, Locatelli M, Pruneri G, Giudici S, Bellomi M, Della Vigna P, Monfardini L, Orsi F, Nolè F, Munzone E, Goldhirsch A. Should liver metastases of breast cancer be biopsied to improve treatment choice? *Ann Oncol*. 2011 Feb 22.

112) Macedo LT, Ribeiro J, **Curigliano G**, Fumagalli L, Locatelli M, Carneiro JB, Quintela A, Bertelli S, De Cobelli O. Multidisciplinary approach in the treatment of patients with small cell bladder carcinoma. *Eur J Surg Oncol*. 2011 Jul;37(7):558-62.

113) Petit JY, Botteri E, Lohsiriwat V, Rietjens M, De Lorenzi F, Garusi C, Rossetto F, Martella S, Manconi A, Bertolini F, **Curigliano G**, Veronesi P, Santillo B, Rotmensz N. Locoregional recurrence risk after lipofilling in breast cancer patients. *Ann Oncol*. 2011 May 24.

114) Munzone E, **Curigliano G**, Burstein HJ, Winer EP, Goldhirsch A. CMF revisited in the 21st century. *Ann Oncol*. 2011 Jun 29.

115) **Curigliano G**. New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance. *Cancer Treat Rev*. 2011 Jul 14.

116) Ribeiro JT, Macedo LT, **Curigliano G**, Fumagalli L, Locatelli M, Dalton M, Quintela A, Carneiro JB, Manunta S, Mazzeo L, Brollo J, Goldhirsch A. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? *Ann Oncol*. 2011 Sep 6

117) **Curigliano G**. Immunity and autoimmunity: revising the concepts of response to breast cancer. *The Breast*. 2011 Oct;20 Suppl 3:S71-4.

118) **G. Curigliano**, Aron Goldhirsch. The Triple-Negative Subtype: New Ideas for the Poorest Prognosis Breast Cancer. *J Natl Cancer Inst Monogr*. 2011;2011(43):108-10.

119) Berruti A, Generali D, Kaufmann M, Puztai L, **Curigliano G**, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petroni P, Di Cosimo S,

Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van't Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010). *J Natl Cancer Inst Monogr.* 2011;2011(43):147-51.

120) Botteri E, Disalvatore D, **Curigliano G**, Brollo J, Bagnardi V, Viale G, Orsi F, Goldhirsch A, Rotmensz N. Biopsy of liver metastasis for women with breast cancer: Impact on survival. *Breast.* 2011 Dec 31

121) **Curigliano G**, Locatelli M, Fumagalli L, Brollo J, Munzone E, Nolè F, Criscitiello C, Goldhirsch A. Targeting the subtypes of breast cancer: rethinking investigational drugs. *Expert Opin Investig Drugs.* 2012 Feb;21(2):191-204. Epub 2012 Jan 10

122) Petit JY, Veronesi U, Orecchia R, **Curigliano G**, Rey PC, Botteri E, Rotmensz N, Lohsiriwat V, Cassilha Kneubil M, Rietjens M. Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. *Ann Oncol.* 2012 Jan 9

123) Peccatori FA, Giovannetti E, Pistilli B, Bellettini G, Codacci-Pisanelli G, Losekoot N, **Curigliano G**, Azim HA Jr, Goldhirsch A, Peters GJ. "The only thing I know is that I know nothing": 5-fluorouracil in human milk. *Ann Oncol.* 2012 Feb;23(2):543-4

124) Munzone E, Botteri E, Sciandivasci A, Curigliano G, Nolè F, Mastropasqua M, Rotmensz N, Colleoni M, Esposito A, Adamoli L, Luini A, Goldhirsch A, Viale G. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. *Breast Cancer Res Treat.* 2012 Apr 1.

125) Brollo J, **Curigliano G**, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: A systematic review of randomized controlled trials. *Cancer Treat Rev.* 2013 Feb;39(1):44-50.

126) Munzone E, Botteri E, Esposito A, Sciandivasci A, Franchi D, Pruneri G, Rotmensz N, **Curigliano G**, Adamoli L, Bocciolone L, Goldhirsch A, Nolè F. Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. *Ann Oncol.* 2012 Apr 29.

127) Kneubil MC, Lohsiriwat V, **Curigliano G**, Brollo J, Botteri E, Rotmensz N, Martella S, Mastropasqua MG, Iera M, Coelho MB, Intra M, Orecchia R, Rey P, Rietjens M, Petit JY. Risk of Locoregional Recurrence in Patients With False-Negative Frozen Section or Close Margins of Retroareolar Specimen in Nipple-Sparing Mastectomy. *Ann Surg Oncol.* 2012 Jul 21.

128) Aurilio G, Munzone E, Botteri E, Sciandivasci A, Adamoli L, Minchella I, Esposito A, Cullurà D, **Curigliano G**, Colleoni M, Goldhirsch A, Nolè F. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. *Breast J.* 2012 Sep;18(5):470-4

129) Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, **Curigliano G**, Goldhirsch A, Nolè F. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. *Clin Breast Cancer.* 2012 Oct;12(5):340-6

130) Peter C. Dubsy and **Giuseppe Curigliano**. Immunotherapy in Breast Cancer – Towards a New Understanding of Both Tumor and Host. *Breast Care* 2012;7:258–260

- 131) Petit JY, Veronesi U, Orecchia R, **Curigliano G**, Rey PC, Botteri E, Rotmensz N, Lohsiriwat V, Cassilha Kneubil M, Rietjens M. Risk factors associated with recurrence after nipple-sparing mastectomy for invasive and intraepithelial neoplasia. *Ann Oncol.* 2012 Aug;23(8):2053-8.
- 132) Peccatori FA, Giovannetti E, Pistilli B, Bellettini G, Codacci-Pisanelli G, Losekoot N, **Curigliano G**, Azim HA Jr, Goldhirsch A, Peters GJ. The only thing I know is that I know nothing": 5-fluorouracil in human milk. *Ann Oncol.* 2012 Feb;23(2):543-4.
- 133) Munzone E, Botteri E, Sciandivasci A, **Curigliano G**, Nolè F, Mastropasqua M, Rotmensz N, Colleoni M, Esposito A, Adamoli L, Luini A, Goldhirsch A, Viale G. Prognostic value of Ki-67 labeling index in patients with node-negative, triple-negative breast cancer. *Breast Cancer Res Treat.* 2012 Jul;134(1):277-82.
- 134) Munzone E, Botteri E, Esposito A, Sciandivasci A, Franchi D, Pruneri G, Rotmensz N, **Curigliano G**, Adamoli L, Bocciolone L, Goldhirsch A, Nolè F. Outcome and clinical-biological characteristics of patients with advanced breast cancer undergoing removal of ovarian/pelvic metastases. *Ann Oncol.* 2012 Nov;23(11):2884-90.
- 135) Kneubil MC, Lohsiriwat V, **Curigliano G**, Brollo J, Botteri E, Rotmensz N, Martella S, Mastropasqua MG, Iera M, Coelho MB, Intra M, Orecchia R, Rey P, Rietjens M, Petit JY. Risk of locoregional recurrence in patients with false-negative frozen section or close margins of retroareolar specimen in nipple-sparing mastectomy. *Ann Surg Oncol.* 2012 Dec;19(13):4117-23.
- 136) Aurilio G, Munzone E, Botteri E, Sciandivasci A, Adamoli L, Minchella I, Esposito A, Cullurà D, **Curigliano G**, Colleoni M, Goldhirsch A, Nolè F. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: a mono-institutional case-cohort report. *Breast J.* 2012 Sep;18(5):470-4
- 137) Munzone E, Botteri E, Sandri MT, Esposito A, Adamoli L, Zorzino L, Sciandivasci A, Cassatella MC, Rotmensz N, Aurilio G, **Curigliano G**, Goldhirsch A, Nolè F. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer. *Clin Breast Cancer.* 2012 Oct;12(5):340-6.
- 138) **Curigliano G**, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, Criscitiello C, Goldhirsch A, Cipolla C, Roila F; ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol.* 2012 Oct;23 Suppl 7:vii155-66.
- 139) Andre F, Dieci MV, Dubsy P, Sotiriou C, **Curigliano G**, Denkert C, Loi S. Molecular pathways: involvement of immune pathways in the therapeutic response and outcome in breast cancer. *Clin Cancer Res.* 2013 Jan 1;19(1):28-33.
- 140) Kneubil MC, Brollo J, Botteri E, **Curigliano G**, Rotmensz N, Goldhirsch A, Lohsiriwat V, Manconi A, Martella S, Santillo B, Petit JY, Rietjens M. Breast cancer subtype approximations and loco-regional recurrence after immediate breast reconstruction. *Eur J Surg Oncol.* 2013 Mar;39(3):260-5.
- 141) Aurilio G, Monfardini L, Rizzo S, Sciandivasci A, Preda L, Bagnardi V, Disalvatore D, Pruneri G, Munzone E, Della Vigna P, Renne G, Bellomi M, **Curigliano G**, Goldhirsch A, Nolè F. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer. *Acta Oncol.* 2013 Jan 17
- 142) Petit JY, Rietjens M, Botteri E, Rotmensz N, Bertolini F, **Curigliano G**, Rey P, Garusi C, De Lorenzi F, Martella S, Manconi A, Barbieri B, Veronesi P, Intra M, Brambullo T, Gottardi A, Sommario M, Lomeo G, Iera M, Giovinazzo V, Lohsiriwat V. Evaluation of fat grafting safety in patients with intra epithelial neoplasia: a matched-cohort study. *Ann Oncol.* 2013 Jun;24(6):1479-84.

- 142) Criscitiello C, **Curigliano G**. HER2 signaling pathway and trastuzumab cardiotoxicity. *Future Oncol*. 2013 Feb;9(2):179-81
- 143) **Curigliano G**. A review of the CTSC-AACR San Antonio Breast Cancer Symposium 2012. *Ecancermedalscience*. 2013;7:291.
- 144) Ferri N, Cazzaniga S, Mazzarella L, **Curigliano G**, Lucchini G, Zerla D, Gandolfi R, Facchetti G, Pellizzoni M, Rimoldi I. Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in Pt(II) complexes on human carcinoma cell lines: a comparative study with cisplatin. *Bioorg Med Chem*. 2013 Apr 15;21(8):2379-86.
- 145) **Curigliano G**, Criscitiello C, Andrè F, Colleoni M, Di Leo A. Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up? *Ecancermedalscience*. 2013 Mar 26;7:299.
- 146) Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, Locatelli MA, Criscitiello C, Lohsiriwat V, Goldhirsch A, Leonardi MC, Orecchia R, **Curigliano G**. Locoregional recurrence in patients with HER2 positive breast cancer. *Breast*. 2013 Apr 30. doi:pii: S0960-9776(13)00078-7.
- 147) Gelao L, Criscitiello C, Fumagalli L, Locatelli M, Manunta S, Esposito A, Minchella I, Goldhirsch A, **Curigliano G**. Tumour dormancy and clinical implications in breast cancer. *Ecancermedalscience*. 2013 May 21;7:320. doi: 10.3332/ecancer.2013.320.
- 148) Ferri N, Cazzaniga S, Mazzarella L, **Curigliano G**, Lucchini G, Zerla D, Gandolfi R, Facchetti G, Pellizzoni M, Rimoldi I. Cytotoxic effect of (1-methyl-1H-imidazol-2-yl)-methanamine and its derivatives in Pt(II) complexes on human carcinoma cell lines: a comparative study with cisplatin. *Bioorg Med Chem*. 2013 Apr 15;21(8):2379-86
- 149) Brollo J, Kneubil MC, Botteri E, Rotmensz N, Duso BA, Fumagalli L, Locatelli MA, Criscitiello C, Lohsiriwat V, Goldhirsch A, Leonardi MC, Orecchia R, **Curigliano G**. Locoregional recurrence in patients with HER2 positive breast cancer. *Breast*. 2013 Oct;22(5):856-62.
- 150) Zurrida S, Bagnardi V, **Curigliano G**, Mastropasqua MG, Orecchia R, Disalvatore D, Greco M, Cataliotti L, D'Aiuto G, Talakhadze N, Goldhirsch A, Viale G. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy. *Eur J Cancer*. 2013 Oct;49(15):3083-92.
- 151) **Curigliano G**, Criscitiello C, Gelao L, Goldhirsch A. Molecular pathways: human leukocyte antigen G (HLA-G). *Clin Cancer Res*. 2013 Oct 15;19(20):5564-71
- 152) Dubsy PC, **Curigliano G**. Immunotherapy in breast cancer - towards a new understanding of both tumor and host. *Breast Care (Basel)*. 2012 Aug;7(4):258-60
- 153) Munzone E, **Curigliano G**, Colleoni M. Tailoring adjuvant treatments for the individual patient with luminal breast cancer. *Hematol Oncol Clin North Am*. 2013 Aug;27(4):703-14.
- 154) Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol*. 2013 Sep;24(9):2206-23
- 155) Mazzarella L, Disalvatore D, Bagnardi V, Rotmensz N, Galbiati D, Caputo S, **Curigliano G**, Pelicci PG. Obesity increases the incidence of distant metastases in oestrogen receptor-negative human epidermal growth factor receptor 2-positive breast cancer patients. *Eur J Cancer*. 2013 Nov;49(17):3588-97
- 156) **Curigliano G**, Pivot X, Cortés J, Elias A, Cesari R, Khosravan R, Collier M, Huang X, Cataruozolo PE, Kern KA, Goldhirsch A. Randomized phase II study of sunitinib versus standard of care for patients with previously treated advanced triple-negative breast cancer. *Breast*. 2013 Oct;22(5):650-6

- 157) Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, **Curigliano G**, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study. *Lancet Oncol*. 2013 Sep;14(10):962-70.
- 158) Wildiers H, Mauer M, Pallis A, Hurria A, Mohile SG, Luciani A, **Curigliano G**, Extermann M, Lichtman SM, Ballman K, Cohen HJ, Muss H, Wedding U. End points and trial design in geriatric oncology research: a joint European organisation for research and treatment of cancer--Alliance for Clinical Trials in Oncology--International Society Of Geriatric Oncology position article. *J Clin Oncol*. 2013 Oct 10;31(29):3711-8.
- 159) **Curigliano G**, Criscitiello C, Esposito A, Fumagalli L, Gelao L, Locatelli M, Minchella I, Goldhirsch A. Developing an effective breast cancer vaccine: challenges to achieving sterile immunity versus resetting equilibrium. *Breast*. 2013 Aug;22 Suppl 2:S96-9
- 160) Criscitiello C, **Curigliano G**. Immunotherapeutics for breast cancer. *Curr Opin Oncol*. 2013 Nov;25(6):602-8
- 161) Criscitiello C, Disalvatore D, Santangelo M, Rotmensz N, Bazolli B, Maisonneuve P, Goldhirsch A, **Curigliano G**. No Link between Breast Cancer and Meningioma: Results from a Large Monoinstitutional Retrospective Analysis. *Cancer Epidemiol Biomarkers Prev*. 2013 Dec 19
- 162) Esposito A, Bardelli A, Criscitiello C, Colombo N, Gelao L, Fumagalli L, Minchella I, Locatelli M, Goldhirsch A, **Curigliano G**. Monitoring tumor-derived cell-free DNA in patients with solid tumors: Clinical perspectives and research opportunities. *Cancer Treat Rev*. 2013 Oct 23. pii: S0305-7372(13)00207-7.
- 163) Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, **Curigliano G**, Adamoli L, Munzone E, Sciandivasci A, De Vita F, Goldhirsch A, Nolè F. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. *Eur J Cancer*. 2013 Nov 21. pii: S0959-8049(13)00904-0
- 164) Criscitiello C, Disalvatore D, De Laurentiis M, Gelao L, Fumagalli L, Locatelli M, Bagnardi V, Rotmensz N, Esposito A, Minchella I, De Placido S, Santangelo M, Viale G, Goldhirsch A, **Curigliano G**. High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. *Breast*. 2014 Feb;23(1):69-75.
- 165) Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, **Curigliano G**, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol*. 2014 Mar;25(3):611-8
- 166) Ballman KV, Mauer M, Wedding U, Mohile SG, Muss H, Extermann M, Luciani A, Cohen HJ, Hurria A, Lichtman SM, **Curigliano G**, Wildiers H. Endpoint in geriatric oncology population. *J Clin Oncol*. 2014 Apr 1;32(10):1090-1
- 167) Cortés J, **Curigliano G**, Diéras V. Expert perspectives on biosimilar monoclonal antibodies in breast cancer. *Breast Cancer Res Treat*. 2014 Apr;144(2):233-9
- 168) Gelao L, Criscitiello C, Esposito A, Goldhirsch A, **Curigliano G**. Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander". *Toxins (Basel)*. 2014 Mar 3;6(3):914-33.

- 169) Criscitiello C, Gelao L, Viale G, Esposito A, **Curigliano G**. Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy. *Expert Opin Investig Drugs*. 2014 May;23(5):599-610.
- 170) **Curigliano G**, Criscitiello C. Successes and limitations of targeted cancer therapy in breast cancer. *Prog Tumor Res*. 2014;41:15-35.
- 171) Gelao L, Criscitiello C, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A, **Curigliano G**. Dendritic cell-based vaccines: clinical applications in breast cancer. *Immunotherapy*. 2014;6(3):349-60.
- 172) Leighl NB, **Curigliano G**. Early-stage lung cancer--what do the experts recommend? *Ann Oncol*. 2014 Aug;25(8):1451-3.
- 173) **Curigliano G**, Perez EA. Immunoscoring breast cancer: TILs remember what they target. *Ann Oncol*. 2014 Aug;25(8):1455-6.
- 174) Maisonneuve P, Disalvatore D, Rotmensz N, **Curigliano G**, Colleoni M, Dellapasqua S, Pruneri G, Mastropasqua MG, Luini A, Bassi F, Pagani G, Viale G, Goldhirsch A. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. *Breast Cancer Res*. 2014 Jun 20;16(3):R65.
- 175) Locatelli M, Criscitiello C, Esposito A, Minchella I, Goldhirsch A, Cipolla C, **Curigliano G**. QTc prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review. *Target Oncol*. 2014 Jun 27.
- 176) Criscitiello C, André F, Thompson AM, De Laurentiis M, Esposito A, Gelao L, Fumagalli L, Locatelli M, Minchella I, Orsi F, Goldhirsch A, **Curigliano G**. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. *Breast Cancer Res*. 2014;16(2):205.
- 177) Pivot X, Gligorov J, Müller V, **Curigliano G**, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group. Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study. *Ann Oncol*. 2014 Oct;25(10):1979-87.
- 178) Esposito A, Criscitiello C, Salè EO, **Curigliano G**. Optimal adjuvant chemotherapy in breast cancer: selection of agents. *Expert Rev Clin Pharmacol*. 2014 Sep;7(5):605-11.
- 179) Criscitiello C, Viale G, Esposito A, **Curigliano G**. Dinaciclib for the treatment of breast cancer. *Expert Opin Investig Drugs*. 2014 Sep;23(9):1305-12.
- 180) Bouche G, André N, Banavali S, Berthold F, Berruti A, Bocci G, Brandi G, Cavallaro U, Cinieri S, Colleoni M, **Curigliano G**, Di Desidero T, Eniu A, Fazio N, Kerbel R, Hutchinson L, Ledzewicz U, Munzone E, Pasquier E, Graciela Scharovsky O, Shaked Y, Stěrba J, Villalba M, Bertolini F. Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan. *Eancermedalscience*. 2014 Sep 9;8:463. doi: 10.3332/ecancer.2014.463. eCollection 2014.
- 181) Lammers P, Criscitiello C, **Curigliano G**, Jacobs I. Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. *Pharmaceuticals (Basel)*. 2014 Sep 17;7(9):943-53.
- 182) **Curigliano G**. 'Tu quoque Brute fili mihi!' (Julius Caesar, Ides of March, 44 BC): role of tumor microenvironment and immune system in breast cancer progression. *Curr Opin Oncol*. 2014 Nov;26(6):543-4.
- 183) Criscitiello C, Esposito A, **Curigliano G**. Tumor-stroma crosstalk: targeting stroma in breast cancer. *Curr Opin Oncol*. 2014 Nov;26(6):551-5.

- 184) Aurilio G, Bagnardi V, Graffeo R, Nolè F, Petit JY, Locatelli M, Martella S, Iera M, Rey P, **Curigliano G**, Rotmensz N, Munzone E, Goldhirsch A. Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer? *Anticancer Res.* 2014 Nov;34(11):6677-83.
- 185) **Curigliano G**. From precision medicine to cancer care through the immunome: highlights from the European Society of Medical Oncology Congress, Madrid, 26-30th September 2014. *Ecancermedicallscience.* 2014 Oct 16;8:472. doi: 10.3332/ecancer.2014.472. eCollection 2014.
- 186) Criscitiello C, Viale G, Gelao L, Esposito A, De Laurentiis M, De Placido S, Santangelo M, Goldhirsch A, **Curigliano G**. Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. *Cancer Treat Rev.* 2015 Feb;41(2):61-68.
- 187) **Curigliano G**, Disalvatore D, Esposito A, Pruneri G, Lazzeroni M, Guerrieri-Gonzaga A, Luini A, Orecchia R, Goldhirsch A, Rotmensz N, Bonanni B, Viale G. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. *Ann Oncol.* 2015 Jan 18. pii: mdv013. [Epub ahead of print]
- 188) Socinski MA, **Curigliano G**, Jacobs I, Gumbiner B, MacDonald J, Thomas D. Clinical considerations for the development of biosimilars in oncology. *MAbs.* 2015 Jan 26:0. [Epub ahead of print]
- 189) **Curigliano G**, Bagnardi V, Bertolini F, Alcalay M, Locatelli MA, Fumagalli L, Rabascio C, Calleri A, Adamoli L, Criscitiello C, Viale G, Goldhirsch A. Antiangiogenic therapy in recurrent breast cancer with lymphangitic spread to the chest wall: A randomized phase II trial of bevacizumab with sequential or concurrent oral vinorelbine and capecitabine. *Breast.* 2015 Jun;24(3):263-71.
- 190) Di Leo A, **Curigliano G**, Diéras V, Malorni L, Sotiriou C, Swanton C, Thompson A, Tutt A, Piccart M. New approaches for improving outcomes in breast cancer in Europe. *Breast.* 2015 Mar 31. pii: S0960-9776(15)00069-7
- 191) Ferri N, Facchetti G, Pellegrino S, Ricci C, **Curigliano G**, Pini E, Rimoldi I. Promising antiproliferative platinum(II) complexes based on imidazole moiety: synthesis, evaluation in HCT-116 cancer cell line and interaction with Ctr-1 Met-rich domain. *Bioorg Med Chem.* 2015 May 15;23(10):2538-47.
- 192) Aurilio G, Bagnardi V, Nolè F, Pruneri G, Graffeo R, Petit JY, Cullurà D, Martella S, Locatelli M, Iera M, Rey P, **Curigliano G**, Rotmensz N, Munzone E, Goldhirsch A. Outcome of Immediate Breast Reconstruction in Patients With Nonendocrine-Responsive Breast Cancer: A Monoinstitutional Case-Control Study. *Clin Breast Cancer.* 2015 Mar 24. pii: S1526-8209(15)00073-7.
- 193) Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel members. Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol.* 2015 May 4. pii: mdv221. [Epub ahead of print]
- 194) Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, **Curigliano G**, Fiorentini C, Cipolla CM. Early Detection of Anthracycline Cardiotoxicity and Improvement With Heart Failure Therapy. *Circulation.* 2015 May 6. pii: CIRCULATIONAHA.114.013777. [Epub ahead of print]
- 194) Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, Thürlimann B, Senn HJ; Panel Members.

Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. *Ann Oncol.* 2015 Aug;26(8):1533-46.

195) Curigliano G, Goldhirsch A. De-escalation attempts for adjuvant trastuzumab: longer beats shorter. *Ann Oncol.* 2015 Jul;26(7):1275-6

196) Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration. Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. *Ann Oncol.* 2015 Jul;26(7):1280-91.

197) Esposito A, Criscitiello C, Curigliano G. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer. *J Natl Cancer Inst Monogr.* 2015 May;2015(51):51-5.

198) Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A. International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013). *J Natl Cancer Inst Monogr.* 2015 May;2015(51):90-6.

199) Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, Ficarra G, Mathieu MC, Delaloge S, Curigliano G, Andre F. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. *Ann Oncol.* 2015 Jul;26(7):1518

200) Santangelo ML, Criscitiello C, Renda A, Federico S, Curigliano G, Dodaro C, Scotti A, Tammaro V, Calogero A, Riccio E, Pisani A, Carlomagno N. Immunosuppression and Multiple Primary Malignancies in Kidney-Transplanted Patients: A Single-Institute Study. *Biomed Res Int.* 2015;2015:183523. doi: 10.1155/2015/183523.

201) Provenzano E, Bossuyt V, Viale G, Cameron D, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Boughey J, Curigliano G, Dixon JM, Esserman L, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Symmans WF; Residual Disease Characterization Working Group of the Breast International Group-North American Breast Cancer Group Collaboration. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group. *Mod Pathol.* 2015 Sep;28(9):1185-201.

202) Criscitiello C, Giuliano M, Curigliano G, De Laurentiis M, Arpino G, Carlomagno N, De Placido S, Golshan M, Santangelo M. Surgery of the primary tumor in de novo metastatic breast cancer: To do or not to do? *Eur J Surg Oncol.* 2015 Oct;41(10):1288-92.

203) Criscitiello C, Curigliano G. Immunotherapy of Breast Cancer. *Prog Tumor Res.* 2015;42:30-43.

204) Esposito A, Criscitiello C, Gelao L, Pravettoni G, Locatelli M, Minchella I, Di Leo M, Liuzzi R, Milani A, Massaro M, Curigliano G. Mechanisms of anorexia-cachexia syndrome and rational for treatment with selective ghrelin receptor agonist. *Cancer Treat Rev.* 2015 Nov;41(9):793-7

205) Criscitiello C, Esposito A, De Placido S, Curigliano G. Targeting fibroblast growth factor receptor pathway in breast cancer. *Curr Opin Oncol.* 2015 Nov;27(6):452-6



- 206) Esposito A, Criscitiello C, Curigliano G. Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications. *Curr Opin Oncol*. 2015 Nov;27(6):445-51
- 207) Curigliano G, Valagussa P, Veronesi U, Gianni L. The influential and inspirational Gianni Bonadonna's life commitment to evidence-based cancer medicine. *Ann Oncol*. 2016 Jan;27(1):6-8. doi: 10.1093/annonc/mdv565. Epub 2015 Nov 23
- 208) Esposito A, Criscitiello C, Locatelli M, Milano M, Curigliano G. Liquid biopsies for solid tumors: Understanding tumor heterogeneity and real time monitoring of early resistance to targeted therapies. *Pharmacol Ther*. 2016 Jan;157:120-4.
- 208) Pravettoni G, Mazzocco K, Gorini A, Curigliano G. Understanding cognitive processes behind acceptance or refusal of phase I trials. *Crit Rev Oncol Hematol*. 2016 Jan 23. pii: S1040-8428(16)30023-3. doi: 10.1016/j.critrevonc.2016.01.023.
- 209) Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, Cipolla CM. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management. *CA Cancer J Clin*. 2016 Feb 26. doi: 10.3322/caac.21341
- 210) Curigliano G, Romieu G, Campone M, Dorval T, Duck L, Canon JL, Roemer-Becuwe C, Roselli M, Neciosup S, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer. *Breast Cancer Res Treat*. 2016 Apr;156(2):301-10. doi: 10.1007/s10549-016-3750-y. Epub 2016 Mar 14.
- 211) Limentani SA, Campone M, Dorval T, Curigliano G, de Boer R, Vogel C, White S, Bachelot T, Canon JL, Disis M, Awada A, Berlière M, Amant F, Levine E, Burny W, Callegaro A, de Sousa Alves PM, Louahed J, Brichard V, Lehmann FF. A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors. *Breast Cancer Res Treat*. 2016 Apr;156(2):319-30.
- 212) Lenihan DJ, Hartlage G, DeCara J, Blaes A, Finet JE, Lyon AR, Cornell RF, Moslehi J, Oliveira GH, Murtagh G, Fisch M, Zeevi G, Iakobishvili Z, Witteles R, Patel A, Harrison E, Fradley M, Curigliano G, Lenneman CG, Magalhaes A, Krone R, Porter C, Parasher S, Dent S, Douglas P, Carver J. Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty. *J Card Fail*. 2016 Jun;22(6):465-71
- 213) Criscitiello C, Bagnardi V, Esposito A, Gelao L, Santillo B, Viale G, Rotmensz N, Goldhirsch A, Curigliano G. Impact of autoimmune diseases on outcome of patients with early breast cancer. *Oncotarget*. 2016 Jun 13. doi: 10.18632/oncotarget.9966. [Epub ahead of print]
- 214) Curigliano G, Gómez Pardo P, Meric-Bernstam F, Conte P, Lolkema MP, Beck JT, Bardia A, Martínez García M, Penault-Llorca F, Dhuria S, Tang Z, Solovieff N, Miller M, Di Tomaso E, Hurvitz SA. Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study. *Breast*. 2016 Aug;28: 191-8
- 215) Pruneri G, Gray KP, Vingiani A, Viale G, Curigliano G, Criscitiello C, Láng I, Ruhstaller T, Gianni L, Goldhirsch A, Kammler R, Price KN, Cancellato G, Munzone E, Gelber RD, Regan MM, Colleoni M. Tumor-infiltrating lymphocytes (TILs) are a powerful prognostic marker in patients with triple-negative breast cancer enrolled in the IBCSG phase III randomized clinical trial 22-00. *Breast Cancer Res Treat*. 2016 Jul;158(2):323-31.
- 216) Criscitiello C, Bagnardi V, Viale G, Disalvatore D, Rotmensz N, Esposito A, Goldhirsch A, Curigliano G. HER2 Equivocal Status in Early Breast Cancer Is Not Associated with Higher Risk of Recurrence. *Anticancer Res*. 2016 Jul;36(7):3537-40.

- 217) Curigliano G, O'Connor DP, Rosenberg JA, Jacobs I. Biosimilars: Extrapolation for oncology. *Crit Rev Oncol Hematol*. 2016 Aug; 104:131-7.
- 218) Tsiatas M, Mountzios G, Curigliano G. Future perspectives in cancer immunotherapy. *Ann Transl Med*. 2016 Jul;4(14):273. doi: 10.21037/atm.2016.07.14
- 219) Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, Habib G, Lenihan DJ, Lip GY, Lyon AR, Lopez Fernandez T, Mohty D, Piepoli MF, Tamargo J, Torbicki A, Suter TM; Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG). 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J*. 2016 Aug 26. [Epub ahead of print]
- 220) Migali C, Milano M, Trapani D, Criscitiello C, Esposito A, Locatelli M, Minchella I, Curigliano G. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. *Ther Adv Med Oncol*. 2016 Sep;8(5):360-74
- 221) Curigliano G. Being more precise in assessing the value of precision medicine in breast cancer. *Breast*. 2016 Oct;29:186-7
- 222) Criscitiello C, Curigliano G, Burstein HJ, Wong S, Esposito A, Viale G, Giuliano M, Veronesi U, Santangelo M, Golshan M. Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? *Eur J Surg Oncol*. 2016 Oct 29. [Epub ahead of print]
- 223) Toesca A, Peradze N, Manconi A, Galimberti V, Intra M, Colleoni M, Bonanni B, Curigliano G, Rietjens M, Viale G, Sacchini V, Veronesi P. Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study. *Breast*. 2016 Oct 29;31:51-56. doi: 10.1016/j.breast.2016.10.009. [Epub ahead of print]
- 224) D'Alesio C, Punzi S, Cicalese A, Fornasari L, Furia L, Riva L, Carugo A, Curigliano G, Criscitiello C, Pruneri G, Pelicci PG, Faretta M, Bossi D, Lanfrancone L. RNAi screens identify CHD4 as an essential gene in breast cancer growth. *Oncotarget*. 2016 Oct 13. doi: 10.18632/oncotarget.12646. [Epub ahead of print]
- 225) Criscitiello C, Esposito A, Trapani D, **Curigliano G**. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. *Cancer Treat Rev*. 2016 Oct 6;50:205-207. doi: 10.1016/j.ctrv.2016.09.019. [Epub ahead of print] Review.
- 226) Curigliano G, Criscitiello C, Esposito A, Pruneri G. Over-using chemotherapy in the adjuvant setting. *Breast*. 2017 Feb;31:303-308
- 227) Curigliano G, Cardoso F, Costa A, Galimberti V, Goldhirsch A, Pelicci PG, Veronesi P, Viale G, Orecchia R. From the maximum tolerable to the minimum effective treatment: The Umberto Veronesi's life commitment to breast cancer care. *Breast*. 2017 Feb;31:241-243.
- 228) Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer. *Oncotarget*. 2016 Nov 30. doi: 10.18632/oncotarget.13727. [Epub ahead of print]
- 229) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Paganì O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines

for Advanced Breast Cancer (ABC 3). *Ann Oncol.* 2016 Dec 5. pii: mdw544. [Epub ahead of print]

230) Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Pernault-Llorca F, Piccart MJ, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E. 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). *Breast.* 2017 Feb;31:244-259.

231) Esposito A, Criscitiello C, Trapani D, Curigliano G. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. *Curr Oncol Rep.* 2017 Jan;19(1):1. doi: 10.1007/s11912-017-0564-y

## PUBLISHED BOOK CHAPTERS

---

1. D. Bossi, F. Wolf, G. Calviello, L. Lauro, **G. Curigliano**, A. Romito and A. Cittadini. Magnesium in the regulation of ascites tumor cell energy metabolism. *Molecular Oncology And Clinical Application* (Birkhauser, Basel). Edited by A. Cittadini, R. Baserga, H.M. Pinedo, T. Galeotti and D. Corda (1993).
2. **G. Curigliano** and G. Ferretti. *Oncogenesi. Trattato di Radioterapia* (2000)
3. **G. Curigliano**. *I sarcomi dei tessuti molli. Trattato di Chirurgia.* Sabiston (Italian Edition 2003)
4. U. Veronesi, F. Bertolini and **G. Curigliano**. *Oncologia. Enciclopedia Treccani*, Edizione 2004
5. **G. Curigliano** et. Al. *Il carcinoma della mammella.* Zanussi. *Trattato di Medicina Interna.* 2007
6. **G. Curigliano** et. Al. *Il carcinoma del testicolo.* Zanussi. *Trattato di Medicina Interna.* 2007
7. **G. Curigliano** et. Al. *Le sindromi paraneoplastiche.* Zanussi. *Trattato di Medicina Interna.* 2007
8. **G. Curigliano**. *Sarcomas of bone and soft tissue.* Greenfield Surgery di Mulholland, Lippincott Williams & Wilkins. 2010
9. F. Bertolini, **G. Curigliano** and U. Veronesi, and. *Oncologia. Enciclopedia Treccani*, Edizione 2010
10. **G. Curigliano**, Janaina Brollo, Maximiliano Cassilha Kneubil. *Systemic Impact of Breast Reconstruction. Reconstructive Breast cancer Surgery.* Mario Rietjens and Cicero Urban Editors. Springer 2012
11. **G. Curigliano**, C. Criscitiello. *Successes and Limitations of Targeted Cancer Therapy in Breast Cancer.* Peters S, Stahel RA (eds): *Successes and Limitations of Targeted Cancer Therapy.* *Prog Tumor Res.* Basel, Karger, 2014, vol 41, pp 15–35
12. Angela Esposito, Lucia Gelao, Carmen Criscitiello and **Giuseppe Curigliano**. *Cardiovascular Toxicity from Chemotherapy and Anticancer Treatment. The Heart and Toxins.* Elsevier 2015
13. Giuseppe Curigliano and Marzia Locatelli. *Arrhythmias and QTc Prolongation. Hot Topics in Medicine and Surgery.* Elsevier 2016.

## SELECTED INTERNATIONAL CONFERENCES ATTENDED AS FACULTY

- 1992 International Conference on Cancer: Molecular Oncology and Clinical Application, Roma, Italia.
- 1993 4th World Congress International Gastro-Surgical Club, Madrid, Spain.
- 1995 5th Congress of the European Council of Coloproctology, Barcellona, Spain.
- 1995 First International Congress "Colorectal Cancer: from Gene to Cure", Amsterdam, Netherland.
- 1995 Research Forum 94<sup>o</sup> Annual Convention of American Society of Colon and Rectal Surgeons, Montreal, Canada.
- 1996 American Association for Cancer Research 87th Annual Meeting, Washington, USA.
- 1996 AARC and IARC Joint Conference "Carcinogenesis from environmental pollution: Assessment of human risk and strategies for prevention", Budapest, Hungary.
- 1996 2nd International Symposium on Predictive Oncology and Therapy "Impact of cancer biotechnology on diagnostic and prognostic indicators in predictive oncology and therapy", Nice, France.
- 1998 European Association for Cancer Research, XV meeting, Stockholm, Sweden.
- 1998 4th International Symposium on Predictive Oncology and Therapy "Impact of biotechnology on cancer: Diagnostic and Prognostic Indicators", Nice, France.
- 2000 2nd Milan Breast Conference, Milan, Italy
- 2000 25th European Society of Medical Oncology Congress, Hamburg, Germany.
- 2000 37th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, USA
- 2001 37th Annual Meeting of the American Society of Clinical Oncology, San Francisco, CA, USA
- 2001 Molecular Targets and Cancer Therapeutics. AACR-NCI-EORTC International Conference, Miami, USA
- 2002 4th Milan Breast Conference, Milan, Italy
- 2003 5th Milan Breast Conference, Milan, Italy

2003 39th Annual Meeting of the American Society of Clinical Oncology, Chicago, USA

2004 6th Milan Breast Conference, Milan, Italy

2004 Molecular Targets and Cancer Therapeutics. AACR-NCI-EORTC International Conference, Geneva, Switzerland

2004 40th Annual Meeting of American Society of Clinical Oncology, New Orleans, USA

2005 41th Annual Meeting of American Society of Clinical Oncology, Orlando, USA

2005 7th Milan Breast Conference, Milan, Italy

2005 96th American Association for Cancer research Annual Meeting Anaheim/Orange County, USA, CA, 2005

2006 42th Annual Meeting of American Society of Clinical Oncology, Atlanta, USA

2006 8th Milan Breast Cancer Conference

2006 97th American Association for Cancer research Annual Meeting Washington, USA, 2006

2006 Saint Gallen Breast Cancer Conference, Saint Gallen, Switzerland

2007 98th American Association for Cancer Research Annual Meeting, Los Angeles, USA

2007 43th Annual Meeting of American Society of Clinical Oncology, Chicago, USA

2007 9th Milan Breast Cancer Conference

2008 10th Milan Breast Cancer Conference

2008 Saint Gallen Breast Cancer Conference, Saint Gallen, Switzerland

2008 Annual Meeting of American Society of Clinical Oncology, Orlando, USA

2008 San Antonio, Breast Cancer Symposium, San Antonio, Texas, USA

2009 Annual Meeting of American Society of Clinical Oncology, Orlando, USA

2009 San Antonio, Breast Cancer Symposium, San Antonio, Texas, USA

2010 ASCO Annual Meeting, Chicago

2010 IMPAKT Breast Cancer Conference, Brussels, Belgium

2011 Saint Gallen Breast Cancer Conference, Saint Gallen, Switzerland

2011 IMPAKT Breast Cancer Conference, Brussels, Belgium

2011 Milan Breast Cancer Conference

2012 IMPAKT Breast Cancer Conference, Brussels, Belgium

2012 ESMO Meeting, Vienna, Invited Speaker and Faculty Member

2013 Saint Gallen Breast Cancer Conference, St Gallen, Switzerland

2013 ECCO Cancer Meeting, Amsterdam

2013 ASCO Annual Meeting, Chicago

2013 Russian Society of Medical Oncology, Moscow

2013 ESTRO annual meeting, Porto

2013 ESSO annual meeting, Amsterdam

2013 San Antonio Breast Cancer Conference

2014 ESMO 2014 Meeting, Madrid, Scientific Chair

2014 IMPAKT Breast Cancer Meeting, Brussels, Scientific Chair

2015 Russian Society of Medical Oncology, Moscow

2015 ESTRO annual meeting, Vienna

2015 ESSO annual meeting, Liverpool

2015 San Antonio Breast Cancer Conference

2015 ECCO 2015 Meeting, Vienna, Invited Speaker

2015 IMPAKT Breast Cancer Meeting, Brussels, Invited Speaker

2015 ABC 3, Advanced Breast Cancer Meeting, Lisboa, Invited Speaker

2016 ESMO Immuno-Oncology Preceptorshipt, Siena, Invited Speaker

2016 UK Breast Cancer Research Symposium, London, UK, Invited Speaker

2016 Forum in Oncology, St Petersburg, Russia, Invited Speaker

2016 ESO-ESMO Masterclass in Medical Oncology, Wolfsberg, Switzerland, Invited Speaker

2016 ESO-ESMO Masterclass in Medical Oncology, Moscow, Russia, Invited Speaker

2016 ESO-ESMO Masterclass in Medical Oncology, Bogotá, Colombia, Invited Speaker

2016 Global Forum in Oncology, New York, USA, Invited Speaker

2016 Workshop in Clinical Oncology, Dubai, United Emirates States, Invited Speaker

2016 UK, Breast Cancer Research Symposium, London, United Kingdom

2016 ESMO Academy, August 26<sup>th</sup> -28<sup>th</sup> Oxford, United Kingdom

2016 2<sup>nd</sup> World Congress on Controversies in Breast Cancer, September 8-11, Barcelona, Spain

2016 ESMO Immuno-Oncology Symposium, Lausanne, Switzerland

## BIOGRAPHICAL SKETCH

Giuseppe Curigliano, MD, PhD, is Chair of the Division of Early Drug Development at European Institute of Oncology, in Milan, Italy, where besides his clinical work. He is a clinician and researcher specializing in breast cancer. Dr. Curigliano earned his MD at the Università Cattolica del Sacro Cuore, in Rome, Italy. He also holds a PhD in clinical pharmacology from the University of Pisa. He completed his postdoctoral fellowship in South Carolina Medical School, Charleston (1993-1994) working on clinical immunology studies in solid tumors. He moved to the Comprehensive Cancer Center at Columbia University in New York City, NY, USA (1995-96). This working experience was concentrated on molecular epidemiology studies related to carcinogen-DNA adducts, susceptibility genes characterization in solid tumors; gene-environment interactions and development of monoclonal antibodies for carcinogen DNA-adducts detection. He moved to the European Institute of Oncology in 1999. He applied to clinical research his strong basic science background leading several translational research protocols on breast and urogenital cancer. He was committed for 3 years in the phase I unit, contributing to successful development of several targeted agents and cytotoxics. Since 2001 he is assistant professor of Clinical Pharmacology at University of Milan. In 2010 he visited Dana Farber Cancer Institute, Harvard Medical School, Boston, USA. He is co-chair of Division of Clinical Oncology coordinating clinical and comprehensive management of patients with all solid tumors (lung, gastrointestinal, urogenital, breast, soft tissue sarcomas and rare tumors). His clinical experience is based on a daily clinical management of patients with solid tumors, within a comprehensive cancer center accepting every year at least 85.000 first diagnosis patients. He practice in the in patient, out patient and day hospital setting. He served for 3 years on emergency and palliative care section of the Division. He is an active member of the American Society of Clinical Oncology (ASCO), the European Society of Medical Oncology (ESMO) and the Associazione Italiana di Oncologia Medica (AIOM). He is founding member of/and scientific coordinator for the International Cardio-Oncology Society (ICOS). He serves on the Clinical Research Committee of the AIOM. He serves as faculty member in the European School of Oncology (ESO). He is member of the Scientific Advisory Committee of the International Breast Cancer Study Group (IBCSG) and of the Breast International Group

(BIG). He is ESMO and ESO Faculty Member for Breast Cancer. He served on the Program Scientific Committee of ESMO 2012 and 2013. He served on the Program Scientific Committee of the St Gallen conference 2009, 2011 and 2013 as scientific secretary. Since October 2011 to May 2012 he served as a Susan G. Komen for the Cure Scholar. He served on the Program Scientific and Executive Committees of the IMPAKT Breast Cancer Conference 2013.

Dr. Curigliano's research experiences include principle or coinvestigator work in several phase I-II clinical trials with targeted agents, cytotoxic and endocrine agents in breast cancer. He has been also involved as principal investigator in several phase I studies with peptide vaccines for breast cancer (either in the adjuvant either in the metastatic setting). Dr Curigliano's research interests include the biology of breast cancer, predictive markers of response to therapy and new anti-cancer agents. He is the coordinator of a research platform on new drug development in breast cancer at European Institute of Oncology. Dr. Curigliano has written widely on oncology, including articles in the Journal of Clinical Oncology, Annals of Oncology, European Journal of Cancer (more than 160 peer reviewed article, most of them as first author) and several book chapters. He also reviews for a number of journals, including the Journal of Clinical Oncology, Annals of Oncology, the Journal of the National Cancer Institute, the European Journal of Cancer and many other "breast oriented journals". He is member of the Editorial Board of Journal of Clinical Oncology, Annals of Oncology, Cancer Treatment Review. He is founding member and Associate Editor for Cardio-Oncology Journal. He serves in the press committee of the European Society of Medical Oncology as Spokesperson coordinator for breast cancer.

Milan, 01.01.2017

Dr. Giuseppe Curigliano has conducted clinical trials according to ICH / GCP. Last training on August 8<sup>th</sup> 2013

Authorizing the processing of personal data as defined by D. Decree Law 196/2003.



Handwritten signature